SSNCMEDIUM SIGNALFINANCIAL10-K

SSNC demonstrates solid operational momentum with 13.1% revenue growth and meaningfully higher operating cash flows, while actively returning capital through increased share buybacks and debt reduction.

The company's financial performance reflects healthy business fundamentals with revenue growth translating to stronger cash generation. Management's confident capital allocation approach—increasing share repurchases by 40.5% while reducing debt by $218 million—signals strong cash flow visibility and commitment to shareholder returns.

Comparing 2026-02-26 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

SSNC delivered balanced growth with revenue increasing 13.1% to $1.7B while operating cash flow expanded 25.7% to $1.7B, demonstrating improved operational efficiency. The company actively deployed capital through $1.0B in share buybacks (up from $737.5M) and reduced total debt by 23.4% to $782M, though cash declined to $462M. Overall asset and liability bases grew modestly, reflecting controlled expansion while maintaining disciplined capital structure management.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+40.5%
$737.5M$1.0B

Share repurchases increased 40.5% — management returning capital, signals confidence in intrinsic value.

Capital Expenditure
Cash Flow
+31.6%
$61.4M$80.8M

Capital expenditure jumped 31.6% — major investment cycle underway; assess returns on deployment.

Operating Cash Flow
Cash Flow
+25.7%
$1.4B$1.7B

Operating cash flow grew 25.7% — strong conversion of earnings to cash, healthy business fundamentals.

Total Debt
Balance Sheet
-23.4%
$1.0B$782.0M

Debt reduced 23.4% — deleveraging strengthens balance sheet and reduces financial risk.

Cash & Equivalents
Balance Sheet
-18.5%
$567.1M$462.1M

Cash decreased 18.5% — monitor burn rate and upcoming capital needs.

Current Liabilities
Balance Sheet
+17.4%
$4.4B$5.1B

Current liabilities rose 17.4% — increased short-term obligations, watch current ratio.

Revenue
P&L
+13.1%
$1.5B$1.7B

Revenue growing 13.1% — solid top-line momentum, watch margins for quality of growth.

Current Assets
Balance Sheet
+12.9%
$4.9B$5.5B

Current assets grew 12.9% — improving short-term liquidity or inventory/receivables build.

Total Liabilities
Balance Sheet
+10.7%
$12.4B$13.8B

Liabilities increased 10.7% — monitor debt-to-equity ratio and interest coverage.

LANGUAGE CHANGES
NEW — 2026-02-26
PRIOR — 2025-03-03
ADDED
There we re 241,505,294 share s of the registrant s common stock outstanding as of February 18, 2026.
SS C s unique business model combines end-to-end expertise across financial services operations with software and solutions to deliver value to customers of any size, scale, or complexity in the financial services and healthcare industries.
Through a series of carefully selected acquisitions, lift outs, and focused research and development, the breadth and depth of SS C s expertise in financial services and healthcare technology are unmatched.
Founded in 1986 and headquartered in Windsor, Connecticut, the Company is home to more than 28,000 employees and has more than 100 offices in 35 countries globally.
We offer clients the flexibility to choose from multiple software delivery options, including on-premise, cloud-based or hosted applications, as well as multi-tenant or dedicated applications.
SS C operates the Intralinks business, a leading provider of secure virtual data room solutions that support mergers and acquisitions, capital raising, investor reporting, and other strategic transactions.
In addition, our 2022 acquisition of Blue Prism enables us to deploy intelligent automation and robotic process automation ( RPA ), including artificial intelligence ( AI ) driven and agentic solutions, to improve the efficiency of our own operations and help clients modernize workflows across financial services and healthcare.
We also serve the healthcare industry through SS C Health, our technology-enabled services and solutions business.
The mission of SS C Health is to help our clients deliver a better healthcare experience.
SS C Health offerings include pharmacy and medical claims processing, clinical and care management programs, population health analytics, digital workforce solutions, and member engagement capabilities.
REMOVED
There were 246,486,228 shares of the registrant s common stock outstanding as of February 19, 2025.
SS C s unique business model combines end-to-end expertise across financial services operations with software and solutions to service even the most demanding customers in the financial services and healthcare industries.
Through a series of carefully selected acquisitions and organic growth, the breadth and depth of SS C s expertise in financial services and healthcare technology are unmatched.
Founded in 1986 and headquartered in Windsor, Connecticut, the Company is home to more than 26,000 employees and has 110 offices in 35 countries globally.
We offer clients the flexibility to choose from multiple software delivery options, including on premise applications and hosted, multi-tenant or dedicated applications.
We also serve the healthcare industry through our SS C Health services and technology-enabled business.
The core purpose of our health business is to enable our clients to provide better healthcare to their members.
With a demonstrated commitment to invest and innovate, our solutions include pharmacy and medical claims processing, clinical programs, population health analytics, digital workers and member engagement, all delivered in a cloud-enabled, cost-efficient service model at scale.
SS C Health targets health plans and pharmacy benefit managers, specifically, those catering to government-funded member segments and those seeking a flexible and scalable alternative to larger integrated vendors.
As a comprehensive health partner, our range of solutions spans across health plan operations.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →